Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03971110
Other study ID # D8664C09827
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date January 28, 2021
Est. completion date November 9, 2022

Study information

Verified date December 2022
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is A Multi-centre, Single-arm, Prospective, Interventional Study to Assess Efficacy and Safety of Neoadjuvant Hormone Therapy using Zoladex (Goserelin) and Casodex (Bicalutamide) in Patients with Advanced Prostate Cancer Undergoing Radical Prostatectomy, to assess the efficacy by resectability rate of neoadjuvant hormone therapy (NHT) in subjects with advanced prostate cancer.


Description:

Neoadjuvant hormonal treatment (NHT) for clinically localised prostate cancer consists of complete androgen blockade (CAB) preceding either radiotherapy or surgery. The rational for this approach is based on the assumption that NHT will reduce both the tumour and normal prostatic tissue volume, and induce cancer regression by the mechanism of apoptosis [1]. Most randomized clinical trials show that NHT reduces the incidence of positive surgical margins after radical prostatectomy and apparently determines tumour downstaging, however no advantage has been documented in terms of biochemical disease progression [for example, time to prostate specific antigen (PSA) increase] between treated and untreated patients [2-8]. Because of relatively low biological aggressiveness of prostatic carcinoma, many patients will need to be followed for a considerable time before drawing significant conclusions on the effects of NHT on survival [2,4,7,10]. A large sample of 393 radical prostatectomy specimens were evaluated in 3 treatment groups, which were immediate surgery, 12 weeks of NHT (Zoladex and Casodex), and 24 weeks of NHT. Patients included clinical stage B (T2a and T2b) and stage C (T3a and T3b). Systemic hormonal treatment, whether 12 weeks or 24 weeks of NHT, is able to "downstage" the primary tumour and decrease the positive margin rate before definitive localised treatment [11]. Currently treatment of patients with oligometastatic prostate cancer is undergoing dramatic changes [12]. The local treatment of the primary tumour might provide a survival benefit to men with metastatic and lymph node-positive disease. Similar observations have been made in treatment of metastatic lesions with life-prolonging, rather than palliative intent [13-17]. This study is proposed primarily to observe the efficacy and safety of 24-week NHT (Zoladex and Casodex) in patients with locally advanced or oligometastatic prostate cancer. Progression status and survival will be followed-up for up to 2 years after NHT. This is a multi-centre, single-arm and prospective study to explore the efficacy and safety of neoadjuvant hormone therapy (NHT) for advanced prostate cancer patients undergoing radical prostatectomy (RP). A total of 104 subjects with locally advanced and oligometastatic prostate cancer at clinical stage of T3 and T4 will be enrolled at almost 20 centres in China. The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously every 12 weeks as neoadjuvant therapy for 24 weeks, and then will be assessed for resectability of the primary tumour. The subjects will undergo a RP [RALP (robot-assisted laparoscopic prostatectomy), laparoscopic RP or RRP (radical retropubic prostatectomy)] plus eLND thereafter if the primary tumour is assessed as resectable. Surgical margin status and involvement of bilateral pelvic lymph nodes will be evaluated. Subjects will be prescribed post-surgical treatment such as continuous ADT and metastasis-directed therapy upon investigator's discretion and be followed-up for up to 2 years. Progression free survival (PFS) and overall survival (OS) will be collected during this study. For the subjects with unresectable primary tumour after NHT, PFS and OS will also be collected in the follow-up for up to 2 years after 24 weeks of CAB.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date November 9, 2022
Est. primary completion date November 9, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Diagnosed within the past 12 months with T2DM according to 1999 WHO criteria 2. Men and women aged at least 18 years at screening. 3. Either not received oral anti-diabetic drugs or had been on short-term (1 month) treatment that had been discontinued 3 months before enrolment. 4. HbA1c = 7.5% and = 10.5% at screening and HbA1c = 7.0% and = 10.5% at pre-randomization visit. 5. FPG = 13.3 mmol/L (= 240 mg/dL) . 6. BMI=18.5 kg/m2 and = 45.0 kg/m2 . 7. C-peptide =0.33nmol/L(=1.0 ng/mL). 8. Able and willing to provide written informed consent and to comply with the study. Exclusion Criteria: 1. Women who are pregnant, intending to become pregnant during the study period, currently lactating females, or women of child-bearing potential not using highly effective, medically approved birth control methods. 2. Diagnosis or history of: 1. Acute metabolic diabetic complications such as ketoacidosis or hyperglycemic hyperosmolar state 2. Diabetes insipidus. 3. Requirement for insulin therapy. Symptoms of poorly controlled diabetes, including but not limited to, marked polyuria and polydipsia with >10% weight loss during the 3 months before enrollment. 4. Triglycerides (fasting) > 9.3 mmol/L (> 800 mg/dL). 5. Patients with clinically apparent hepatobiliary disease, including but not limited to chronic active hepatitis and/or severe hepatic insufficiency. ALT or AST > 3x upper limit of normal (ULN), or serum total bilirubin (TB) >34.2 µmol/L (>2 mg/dL). 6. Patiens with following renal disease history or renal disease related features: 1. History of unstable or rapidly progressing renal disease; 2. Patients with moderate /severe renal impairment or end-stage renal disease (eGFR< 60 mL/min/1.73 m2) 3. Urinary albumin: creatinine ratio >1800 mg/g; 4. Serum creatinine (Cr) =133 µmol/L (=1.50 mg/dL) for male subjects; Serum Cr=124 µmol/L (=1.40 mg/dL) for female subjects; 5. Conditions of congenital renal glycosuria. 7. Severe uncontrolled hypertension defined as SBP =180 mmHg and/or BP =110 mmHg;Patients with SBP < 95mmHg. 8. Any of the following cardiovascular diseases within 6 months of the enrollment visit: 1. Myocardial infarction; 2. Cardiac surgery or revascularization (coronary artery bypass graft/percutaneous transluminal coronary angioplasty); 3. Unstable angina; 4. Congestive heart failure New York Heart Association Class III or IV; 5. Transient ischemic attack or significant cerebrovascular disease. 9. History of gastrointestinal disease or surgery including Roemheld Syndrome, severe hernia, intestinal obstruction, intestinal ulcer, gastroenterostomy, enterectomy, bariatric surgery or lap-band procedure. 10. Malignancy within 5 years of the enrollment visit (with the exception of treated basal cell or treated squamous cell carcinoma). 11. Known immunocompromised status, including but not limited to, individuals who had undergone organ transplantation or acquired immunodeficiency syndrome (AIDS). 12. Any subject who, in the judgment of the investigator, was at risk for dehydration or volume depletion that might affect the interpretation of efficacy or safety data. 13. History of bone fracture secondary to diagnosed severe osteoporosis. 14. Currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases as judged by the Investigator. 15. Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for >4 weeks within 3 months before enrollment visit. 16. Administration of sibutramine, phentermine, orlistat, rimonabant, benzphetamine, diethylpropion, methamphetamine, or phendimetrazine within 30 days of enrollment visit. 17. Any subject who was currently abusing alcohol or other drugs or had done so within the last 6 months 18. Donation of blood or blood products, blood transfusion, or participation in a clinical study requiring withdrawal of >400 mL of blood during the 6 weeks before the enrollment visit 19. History of hypersensitivity reaction to dapagliflozin or acarbose. Allergies or contraindication to the contents of dapagliflozin tablets or acarbose tablests. 20. Previous participation in a clinical trial with dapagliflozin. 21. Administration of any other investigational drug within 30 days of planned enrollment to this study, or within 5 half-life periods of other investigational drugs. 22. Subject is, in the judgment of the Investigator, unlikely to comply with the protocol or has any severe concurrent medical or psychological condition that may affect the interpretation of efficacy or safety data.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Zoladex and Casodex
The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.

Locations

Country Name City State
China Research Site Beijing
China Research Site Changsha
China Research Site Changsha
China Research Site Chengdu
China Research Site Guangzhou
China Research Site Guangzhou
China Research Site Hangzhou
China Research Site Hangzhou
China Research Site Hefei
China Research Site Shanghai
China Research Site Shenyang
China Research Site Shijiazhuang
China Research Site Urumqi
China Research Site Xi'an
China Research Site Zhengzhou

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

China, 

References & Publications (1)

1. Montironi R, Schulman CC. Pathological changes in prostate lesions after androgen manipulation. J Clin Pathol 1998; 51:5-12. 2. Witjes WP, Schulman CC, Debruyne FM. Preliminary results of a prospective randomized study comparing radical prostatectomy v

Outcome

Type Measure Description Time frame Safety issue
Primary Resectability rate for primary tumour (the resectability will be assessed by central review using a digital rectal examination and confirmed by CT or MRI) To assess the efficacy by resectability rate of neoadjuvant hormone therapy (NHT) in subjects with advanced prostate cancer at 24 week
Secondary Radical prostatectomy rate Which will be derived using the number of patient who will conduct the radical prostatectomy at 24 week. From baseline to 24 week
Secondary The mean PSA by the end of NHT which will be derived using the value of mean PSA by the end of NHT From baseline to 24 week
Secondary Percentage of positive surgical margin for primary tumour Which will be derived using the number of positive surgical margin at 24 week From baseline to 24 week
Secondary Incidence of seminal vesicle invasion Which will be derived using the value of incidence of seminal vesicle invasion at 24 week From baseline to 24 week.
Secondary Percentage of pathological downstaging Which will be derived using the number of pathological downstaging at 24 week. From baseline to 24 week
Secondary surgical-related variables at 12 weeks, potent rates in erectile function at 12 weeks after surgery Which will be derived using the value of observe surgical-related variables and complications at week 36 From 24 week to 36 week
Secondary PFS Which will be derived using the number of PFS at the end of study From baseline to the end of study
Secondary AEs/SAEs To evaluate the safety of NHT using goserelin and bicalutamide From baseline to 28 week
Secondary PSA change from baseline Which will be derived using the value of PSA at the baseline. From baseline to 24 week
Secondary Involvement of bilateral pelvic lymph nodes Which will be derived using the value of involvement of bilateral pelvic lymph nodes at 24 week. From baseline to 24 week
Secondary OS Which will be derived using the number of OS at the end of study. From baseline to the end of study
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06006104 - Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer Phase 1/Phase 2
Recruiting NCT03936218 - Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer Phase 3
Completed NCT02234089 - Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
Completed NCT01078545 - Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS) N/A
Active, not recruiting NCT03511196 - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Early Phase 1
Recruiting NCT05942001 - Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Phase 1
Active, not recruiting NCT04117594 - Whole Body Magnetic Resonance Imaging Study
Not yet recruiting NCT06369246 - PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer Phase 2
Completed NCT01383863 - A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer
Completed NCT03651271 - Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer Phase 2
Active, not recruiting NCT05590793 - Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate Phase 3
Recruiting NCT06095089 - A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer Phase 1
Active, not recruiting NCT02787837 - PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.
Active, not recruiting NCT02362620 - PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.
Recruiting NCT05800665 - A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer Phase 1
Recruiting NCT03938649 - SRAM study_Postate Cancer Phase 2
Completed NCT00871585 - Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide N/A
Active, not recruiting NCT02922218 - PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.
Not yet recruiting NCT06335914 - Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer N/A
Terminated NCT03577028 - Study of HPN424 in Patients With Advanced Prostate Cancer Phase 1/Phase 2